Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 4,199 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Injection Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

NCT04228783
View directory record Official record
Conditions
Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

NCT06102005
View directory record Official record
Conditions
Asthma
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
48
States / cities
Scottsdale, Arizona • Yuma, Arizona • Lancaster, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx

NCT04083222
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, ISIS 757456
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Tustin, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 19, 2026, 8:21 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

NCT07512427
View directory record Official record
Conditions
MASH
Interventions
OPK-88006, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

NCT06465186
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
Interventions
Efinopegdutide, Placebo
Combination Product
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
33
States / cities
Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 8:21 PM EDT
Not listed Phase 1Phase 2 Interventional

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

NCT01947569
View directory record Official record
Conditions
Treatment of Type I Diabetes Mellitus.
Interventions
Biological
Biological
Lead sponsor
DiaVacs, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis

NCT03450083
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Nasal Polyps, Eosinophilia
Interventions
Benralizumab, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

NCT04681066
View directory record Official record
Conditions
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
Interventions
CM-4620 Injectable Emulsion or CM-4620-IE, Placebo
Drug · Other
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women

NCT00222872
View directory record Official record
Conditions
Osteoporosis, Osteoporosis, Postmenopausal
Interventions
Parathyroid Hormone-related Protein, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

NCT00590577
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo, Paliperidone palmitate 100 mg eq.
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 1Phase 2 Interventional

OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

NCT04129775
View directory record Official record
Conditions
Sensorineural Hearing Loss
Interventions
OTO-413, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
21 Years to 64 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Colorado Springs, Colorado • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Sedatives on Tobacco Use Disorder Version 2

NCT05505630
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Ketamine, Midazolam, Dexmedetomidine, Saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 19, 2026, 8:21 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?

NCT07452094
View directory record Official record
Conditions
Placebo - Control, Experimental
Interventions
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Drug
Lead sponsor
Northern Arizona University
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Early Treatment for Acute ACL Tear

NCT01692756
View directory record Official record
Conditions
Anterior Cruciate Ligament (ACL) Tears
Interventions
Kenalog or placebo, Kenalog then Placebo, Kenalog, Placebo
Drug
Lead sponsor
Cale Jacobs
Other
Eligibility
14 Years to 33 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 19, 2026, 8:21 PM EDT
Terminated Phase 4 Interventional Results available

Sputum-derived Cellular Targets After Xolair (Omalizumab)

NCT02658877
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 19, 2026, 8:21 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

NCT02945046
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mesenchymal Stem Cells for the Treatment of COVID-19

NCT04573270
View directory record Official record
Conditions
Covid19, Prophylaxis
Interventions
PrimePro, Placebo
Biological · Other
Lead sponsor
Thomas Advanced Medical LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 19, 2026, 8:21 PM EDT
Active, not recruiting Phase 4 Interventional

GnRH for Luteal Support in IVF/ICSI/FET Cycles

NCT02357654
View directory record Official record
Conditions
Infertility
Interventions
GnRH, placebo
Drug
Lead sponsor
University Reproductive Associates
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Hasbrouck Heights, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06130566
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Scottsdale, Arizona • Fountain Valley, California • Fremont, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 3 Interventional Results available

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

NCT01813422
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
59
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

NCT00289341
View directory record Official record
Conditions
Prostate Cancer
Interventions
vaccine vehicle only, DC/LNCaP
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women

NCT03640754
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
G-CSF, Placebo/Saline
Biological · Other
Lead sponsor
MenoGeniX, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 19, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation

NCT00487656
View directory record Official record
Conditions
Sepsis, Disseminated Intravascular Coagulation
Interventions
ART-123, placebo
Drug
Lead sponsor
Artisan Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Oct 19, 2026, 8:21 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437
View directory record Official record
Conditions
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ponsegromab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 8:21 PM EDT